Home > Insider Trading > Filing (0001209191-20-015654)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1787297	Passage Bio Inc.	PASG	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1365617	J Patrick Heron	601 Union Street Seattle WA 98101		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-03	2,977,242	$0.00	2,977,242	No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
Common Stock	Acquisiton	2020-03-03	1,049,175	$0.00	4,026,417	No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
Common Stock	Acquisiton	2020-03-03	432,802	$0.00	4,459,219	No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
Common Stock	Acquisiton	2020-03-03	550,000	$18.00	5,009,219	No	4	P	Indirect	By Frazier Life Sciences IX, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
No	4	C	Indirect	By Frazier Life Sciences IX, L.P.
No	4	P	Indirect	By Frazier Life Sciences IX, L.P.

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2020-03-03	2,977,242	$0.00	2,977,242	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2020-03-03	1,049,175	$0.00	1,049,175	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-03-03	432,802	$0.00	432,802	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

Each share of the issuer's Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020.
These securities are held of record by Frazier Life Sciences IX, L.P. ("Frazier Life Sciences"), of which FHMLS IX, L.P. ("FHMLS L.P.") is the general partner. FHMLS IX, L.L.C. ("FHMLS LLC") is the general partner of FHMLS L.P. The reporting person and James N. Topper are the managing members of FHMLS LLC and may be deemed to have shared voting and dispositive power over the shares held by Frazier Life Sciences. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.